Lyell Immunopharma, Inc.
LYEL· Nasdaq
LYELLyell Immunopharma, Inc.
Filed Mar 29, 2022 · 10-K · 88 days after period end · 0001628280-22-007708
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|
| Revenue | $2.82M | — |
| Net Income | -$83.71M | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lyell Immunopharma, Inc. · CIK 1806952 · Engraved from SEC EDGAR
ended Dec 31, 2021 · filed Mar 29, 2022 · 88 d after period end
